Smith & Nebhew plc announced the launch of the ALLEVYN COMPLETE CARE Foam Dressing, a five‑layer wound dressing designed to manage chronic wounds and prevent pressure injuries. The new dressing is available in the United States today and will be rolled out to European and other international markets during 2026.
The ALLEVYN COMPLETE CARE Foam Dressing incorporates proprietary technologies that lock in exudate, keep bacteria out, and dissipate shear forces. These features allow longer wear times and fewer dressing changes, reducing nursing time and overall healthcare costs while improving patient outcomes.
The launch is part of Smith & Nebhew’s Advanced Wound Management portfolio, which grew 10.2% underlying revenue in H2 2025 and contributed to the company’s free‑cash‑flow transformation. In FY 2025 the portfolio grew over 5% underlying revenue, and the company’s FY 2025 revenue reached $6.2 billion with a 5.3% underlying increase. The new dressing aligns with the company’s RISE strategy, launched in December 2025, and supports the innovation pillar of that strategy.
The chronic wound and pressure injury market is projected to reach billions of dollars. In the United States, 1 in 10 hospitalized patients are affected by pressure injuries, which drive $26.8 billion in annual healthcare costs. By adding a high‑margin, high‑volume product line, Smith & Nebhew aims to capture a share of this expanding market and further strengthen its position as a leader in advanced wound care solutions.
Smith & Nebhew forecasts organic revenue growth of around 6% and trading profit growth of about 8% for 2026. The ALLEVYN COMPLETE CARE Foam Dressing is expected to contribute to this growth by adding a new high‑margin product line. The dressing builds on the successful ALLEVYN LIFE line and is supported by internal reports, in‑vitro testing, and modeling presented at scientific conferences.
The launch strengthens Smith & Nebhew’s Advanced Wound Management portfolio, positions the company to lower healthcare costs and improve patient outcomes, and supports the company’s broader growth strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.